Theodoros Foukakis
Overview
Explore the profile of Theodoros Foukakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
3268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boman C, Tranchell C, Liu X, Eriksson Bergman L, Toli M, Bergh J, et al.
J Natl Compr Canc Netw
. 2025 Mar;
:1-7.
PMID: 40073831
Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) for early-stage breast cancer is prognostic, but not the sole surrogate marker for long-term outcome at a trial level, given that...
2.
Dent R, Cortes J, Park Y, Munoz-Couselo E, Kim S, Sohn J, et al.
Breast Cancer Res
. 2025 Mar;
27(1):35.
PMID: 40069763
Background: The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer (TNBC). This exploratory analysis evaluated features of the...
3.
Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):23.
PMID: 40055382
Breast cancer (BC) represents a heterogeneous ecosystem and elucidation of tumor microenvironment components remains essential. Our study aimed to depict the composition and prognostic correlates of immune infiltrate in early...
4.
Tsiknakis N, Wang K, Salgkamis D, Tzoras E, Manikis G, Sifakis E, et al.
Annu Int Conf IEEE Eng Med Biol Soc
. 2025 Mar;
2024:1-5.
PMID: 40039878
Developing AI models on medical images as decision support systems has seen a huge increase in interest during the last few years. However, most published studies have neglected testing the...
5.
Zerdes I, Filis P, Fountoukidis G, El-Naggar A, Kalofonou F, DAlessio A, et al.
J Natl Cancer Inst
. 2025 Jan;
PMID: 39842854
Background: Although precision oncology has rapidly been developed in recent years, its real-world impact and challenges in healthcare implementation remain underexplored. Through a meta-analysis of real-world evidence (RWE), we aimed...
6.
Liu X, Eriksson Bergman L, Boman C, Foukakis T, Matikas A
Eur J Surg Oncol
. 2025 Jan;
51(3):109587.
PMID: 39794172
Introduction: Although neoadjuvant systemic treatment for non-metastatic breast cancer has gained ground during the past decade, there is no compelling evidence that it improves overall survival compared to primary tumor...
7.
Filis P, Markozannes G, Chan D, Mauri D, Foukakis T, Matikas A, et al.
Crit Rev Oncol Hematol
. 2024 Dec;
207:104602.
PMID: 39730034
Background: To contribute to the refinement of future physical activity (PA) guidelines, which have remained mostly generic until now, we performed an umbrella review of meta-analyses for PA in cancer...
8.
Kouvaraki M, Zerdes I, Sifakis E, Sarafidis M, Matikas A, Tzoras E, et al.
Int J Cancer
. 2024 Dec;
156(8):1621-1633.
PMID: 39729390
Sterile alpha motif and HD domain-containing protein 1 (SAMHD1) is a dNTP hydrolase important for intracellular dNTP homeostasis and serves as tumor suppressor and modulator of antimetabolite efficacy in cancer,...
9.
Zouzos A, Fredriksson I, Karakatsanis A, Aristokleous I, Foukakis T, Strand F
Eur J Radiol
. 2024 Dec;
183:111895.
PMID: 39724795
Background: Utilizing a larger needle-size instead of a smaller one in vacuum-assisted excision of breast lesions might enhance the effectiveness of the method. We conducted a clinical trial to investigate...
10.
Matikas A, Papakonstantinou A, Loibl S, Steger G, Untch M, Johansson H, et al.
Lancet Reg Health Eur
. 2024 Dec;
49:101162.
PMID: 39703564
Background: It is unclear whether some patients with high-risk breast cancer do not warrant adjuvant dose-dense chemotherapy due to small expected absolute benefit. Methods: The phase 3 PANTHER trial (NCT00798070)...